OIS-ASCRS 2017
ZeptoTM
ZeptoTM Update
• US clinical trial completed in 80 days.
• 510(k) submitted to FDA March 3, 2017
• ZeptoTM launched, India (Feb 2017), Germany (Mar 2017), US launch
(~ Summer 2017).
• Funding round completed. Target cash flow positive by year end.
• ZeptoTM as visual axis reference marker to guide surgery.
• Development of ZeptoTM for posterior capsulotomy.
Anchoring Cataract Surgery
On The Visual Axis Using ZeptoTM
LIGHT
EYEPIECE
COAXIAL
SURGEON
PATIENT
INTRAOPERATIVE
USE OF COAXIAL
PURKINJE IMAGE
IDENTIFY & CENTER
ON P1 PURKINJE IMAGE
Anchoring Cataract Surgery
On The Visual Axis Using ZeptoTM
Automated ZeptoTM
Posterior Capsulotomy
So, What Does ZeptoTM Add
For Physicians & Patients?
ZeptoTM Cataract
Surgery
Fast, consistent,
high quality
capsulotomies for
everyone
Increase practice
efficiency
Possibility of PCO
prevention, re-
defining cataract
surgery
Anchor surgery To
visual axis
(premium &
general market)
Make difficult
cases, easy and
safe
What Everyone Wants…
1. Large market
2. Clear product need
3. Customers come to you
4. Easy integration into current portfolio
5. Treats all or large patient segments
6. Enhances current products sales
7. Pulls customers to high margin products
8. Minimal change to physician practice
9. Minimal physician and sales force learning curve
10. Market longevity
11. Little to no competition
12. Technology leads to additional markets
✔
✔
✔
✔
✔
✔
✔
✔
✔
✔
✔
✔
How Does ZeptoTM Provide Value?
Rare, compelling business tool
More than simply an innovative device
Once in a generation product
Phaco, OVD, foldable IOL……
Positioned to be gold-standard and
re-define cataract surgery
Zepto
Markets & Leadership
Be the first to implement better technology
immediately whenever it becomes available, and
then make it an industry standard.
Steve Jobs
Zepto Is Everywhere!
Zepto
Zepto
Zepto
Zepto
Zepto
Zepto
ZeptoZeptoZepto
Zepto
Zepto
Zepto
Zepto
Zepto
Zepto
OIS-ASCRS 2017

Ophthalmology Innovation Showcase 2 - Mynosys Cellular Devices

  • 1.
  • 2.
  • 3.
    ZeptoTM Update • USclinical trial completed in 80 days. • 510(k) submitted to FDA March 3, 2017 • ZeptoTM launched, India (Feb 2017), Germany (Mar 2017), US launch (~ Summer 2017). • Funding round completed. Target cash flow positive by year end. • ZeptoTM as visual axis reference marker to guide surgery. • Development of ZeptoTM for posterior capsulotomy.
  • 4.
    Anchoring Cataract Surgery OnThe Visual Axis Using ZeptoTM LIGHT EYEPIECE COAXIAL SURGEON PATIENT INTRAOPERATIVE USE OF COAXIAL PURKINJE IMAGE IDENTIFY & CENTER ON P1 PURKINJE IMAGE
  • 5.
    Anchoring Cataract Surgery OnThe Visual Axis Using ZeptoTM
  • 6.
  • 7.
    So, What DoesZeptoTM Add For Physicians & Patients? ZeptoTM Cataract Surgery Fast, consistent, high quality capsulotomies for everyone Increase practice efficiency Possibility of PCO prevention, re- defining cataract surgery Anchor surgery To visual axis (premium & general market) Make difficult cases, easy and safe
  • 8.
    What Everyone Wants… 1.Large market 2. Clear product need 3. Customers come to you 4. Easy integration into current portfolio 5. Treats all or large patient segments 6. Enhances current products sales 7. Pulls customers to high margin products 8. Minimal change to physician practice 9. Minimal physician and sales force learning curve 10. Market longevity 11. Little to no competition 12. Technology leads to additional markets ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔ ✔
  • 9.
    How Does ZeptoTMProvide Value? Rare, compelling business tool More than simply an innovative device Once in a generation product Phaco, OVD, foldable IOL…… Positioned to be gold-standard and re-define cataract surgery Zepto
  • 10.
    Markets & Leadership Bethe first to implement better technology immediately whenever it becomes available, and then make it an industry standard. Steve Jobs
  • 11.
  • 12.